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PAI-1 mRNA in kidney was decreased at 24 months in AIIRARegression of sclerosis in aging by angiotensin inhibition-induced
versus age-matched controls (PAI-1/GAPDH density ratio:decrease in PAI-1.
AIIRA 24 months 0.34 6 0.05 vs. 24-month controls 0.99 6Background. Glomerular and vascular sclerosis increase
0.05, P , 0.05). Increased glomerular PAI-1 immunostainingwith aging, and angiotensin inhibitors ameliorate progression
with aging was decreased by AIIRA at 24 months versus age-of this injury. We investigated the potential for achieving re-
matched controls, even below baseline (staining score 0 to 41,gression of existing age-related sclerosis, and the mechanisms
0.57 6 0.15 vs. control 0.90 6 0.07, P , 0.05; baseline 1.05 6by which angiotensin type 1 receptor antagonist (AIIRA) may
0.02, P , 0.01).affect remodeling of this sclerosis. We focused on plasminogen
Conclusion. We conclude that AIIRA not only slows theactivator inhibitor-1 (PAI-1) because it is directly induced by
progression of glomerular and vascular sclerosis in aging, butangiotensin, inhibits matrix degradation, and may thus be piv-
otal in remodeling. can also induce regression of these processes. The mechanisms
Methods. Eighteen-month-old male Sprague-Dawley rats were appear to involve modulation of cortical cell turnover and
treated with the AIIRA losartan (N 5 8, 80 mg/L, dry weight), inhibition of PAI-1 expression.
sacrificed at age 21 and 24 months, and compared with age-
matched untreated controls (N 5 15). Blood pressure and renal
function were monitored, and morphological, biochemical, and
Aging is a complex physiological condition in whichmolecular analyses were done on aorta and kidney.
the function of many organ systems becomes altered.Results. Body weight increased in both groups. Mean arte-
rial pressure (MAP) and serum creatinine remained normal The changes in kidney functions along with its morphol-
(24-month MAP 115 6 8 vs. 113 6 6 mm Hg, controls vs. ogy are among the most dramatic. Glomerulosclerosis
AIIRA, P 5 NS). Aorta wall thickness ratio was reduced by and tubulointerstitial fibrosis are hallmarks of progres-AIIRA at 21 and 24 months vs. age-matched controls (21 months
sive forms of renal disease of diverse etiologies and are0.12 6 0.01 vs. 0.15 6 0.01, P 5 0.006; 24 months 0.10 6 0.005
frequently present in kidneys from aged animals andvs. 0.14 6 0.003, AIIRA vs. controls, respectively, P 5 0.0027).
The aorta wall thickness ratio after treatment with AIIRA for humans. In addition, aging kidneys show hypertrophy of
six months was even lower than that of 18-month control rats glomeruli, mesangial matrix expansion, increased thick-
(P 5 0.018). AIIRA reduced proteinuria versus age-matched
ness of basement membranes, arterial thickening, andcontrol at 24 months (253 6 62 vs. 390 6 51 mg/24 h, P 5
hyalinosis [1].0.0017). AIIRA at 24 months decreased glomerulosclerosis
versus age-matched control (sclerosis index, 0 to 41 scale: 0.06 6 Among the mechanisms underlying renal scarring, we
0.02 vs. 0.49 6 0.12, P 5 0.0082) to levels even lower than the postulate that plasminogen activator inhibitor-1 (PAI-1)
18-month baseline (0.37 6 0.14, P 5 0.014). Renal collagen plays a critical role because of its effects on fibrinolysis
content increased with aging and was decreased by AIIRA at
and turnover of extracellular matrix (ECM) protein.24 months (5.0 6 0.7 vs. 3.1 6 0.5% collagen, P , 0.05).
PAI-1, a member of the superfamily of serine proteaseApoptosis, assessed by TUNEL, was increased in tubular and
interstitial cells in aging and was reduced by AIIRA versus inhibitors, is a major physiological inhibitor of tissue-
control and baseline, respectively (TUNEL scoring, AIIRA 24 type plasminogen activator (t-PA) and urokinase-type
months 0.33 6 0.16 vs. 1.06 6 0.23 and 0.80 6 0.05, P , 0.05). plasminogen activator (u-PA), both of which activate
plasminogen to plasmin, thus promoting fibrinolysis.
PAI-1 is produced by multiple sources, including endo-Key words: kidney aorta, aorta, fibrosis, collagen, AIIRA, progressive
renal disease, cortical cell turnover. thelium, vascular smooth muscle cells, liver, platelets,
mesangial cells, and epithelial cells [2, 3]. In addition toReceived for publication March 24, 2000
its known effects to promote thrombosis by inhibitingand in revised form May 23, 2000
Accepted for publication June 21, 2000 t-PA and u-PA, PAI-1 has important potential effects on
matrix degradation, since plasmin and t-PA and u-PAÓ 2000 by the International Society of Nephrology
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are not only fibrinolytic but are also proteolytic and can monthly for 24-hour urine collection. Twenty-four–hour
urine protein was measured by Bio-Rad Protein Assayactivate other matrix metalloproteinases (MMPs) from
latent to active states. Up-regulation of PAI-1 can thus Kit (Bio-Rad Laboratories, Hercules, CA, USA).
inhibit degradation of ECM, leading to accumulation of
Kidney and aorta morphologyECM.
Many factors can regulate PAI-1 synthesis, including A cross-sectional portion of the kidney and the arch of
the aorta were immersion fixed in 4% paraformaldehyde,angiotensin II (Ang II). Ang II not only stimulates expres-
sion of PAI-1 in vitro [4], but also promotes a rapid and 4 mm sections were stained with periodic acid-Schiff
and Masson’s trichrome. Immunohistochemistry and inincrease in PAI-1 in vivo in humans [5] and rats [6],
not dependent on its hemodynamic action. Inhibition of situ hybridization studies were performed (discussed
later in this article). A semiquantitative score [sclerosisAng II type 1 (AT1) receptor-mediated Ang II actions
abolished the increased PAI-1 mRNA and protein ex- index (SI)] was used to evaluate the degree of glomerular
sclerosis. The severity of sclerosis for each glomeruluspression in kidney, heart, aorta, and liver in the rat [6].
Moreover, chronic inhibition of the renin-angiotensin was graded from 0 to 41 as follows: 0 represents no
lesion, 11 sclerosis of ,25% of the glomerulus, whilesystem (RAS) prevented renal injury following radiation
via suppression of PAI-1 expression [7]. The develop- 21, 31, and 41 represent sclerosis of 25 to 50%, 50 to
75%, and .75% of the glomerulus, respectively. A whole-ment of renal interstitial fibrosis [8, 9], glomerulosclero-
sis, and arterial wall sclerosis in aging mice and rats [10] kidney average SI was obtained by averaging scores from
all glomeruli on one section. Tubulointerstitial fibrosishas been slowed by angiotensin I-converting enzyme in-
hibitor (ACEI). In the present study, we tested the was evaluated qualitatively on Masson’s trichrome-stained
section.hypotheses that existing renal and vascular sclerosis in
aging can be reversed by angiotensin type 1 receptor The circumference of the outer (a) and inner (b) layer
of a cross section of aorta was measured using a compu-antagonist (AIIRA) and that inhibition of PAI-1 contrib-
utes to this regression. terized planimeter (Micro-plan 2; Donsanto Corp., Na-
tick, MA, USA). The wall thickness ratio of the aortic
wall was expressed as: (a–b)/a.
METHODS
Experimental design and animals Collagen content
Renal cortex was isolated and frozen, and collagen con-Aging male Sprague-Dawley rats from Zivic Miller
Laboratories (Zellenople, PA, USA) were studied. Aging tent was calculated from the concentration of hydroxy-
proline and proline, measured as their phenylisothio-rats were housed under controlled conditions with a
12-hour light/dark cycle, at 708F with 40% humidity and cyanate derivatives by reverse-phase high-performance
liquid chromatography (RP-HPLC) [11]. Briefly, tissue12 air exchanges per hour. Rats received normal rat chow
and water ad libitum (“5001” diet; Rodent diet, 23.4% homogenates were hydrolyzed in vacuo in constant boiling
HCl (1108C, 16 hours) and were dried and taken up inprotein, 4.5% fat, 6.0% fiber, 0.40% sodium; Purina Lab-
oratory; St. Louis, MO, USA). At 18 months of age, 1 mL of “redrying solution” [ethanol/water/(C2H5)3N,
2:2:1], and 100 mL was redried under nitrogen. Twentytreatment with the Ang II type I receptor antagonist
losartan (21-month AIIRA, N 5 4; 24-month AIIRA, microliters of derivatization reagent [ethanol/water/
(C2H5)3N/phenylisothio-cyanate, 7:1:1:1] were added,N 5 4, 80 mg/L drinking water, resulting in a dose of
5 mg/kg/day) was begun, and rats were sacrificed at the and the reaction was allowed to proceed at room temper-
ature for 20 minutes. The sample was then lyophilizedage of 21 or 24 months and were compared with age-
matched untreated controls (18-month control, N 5 5; during centrifugation to remove the reagents. Samples
were either frozen at this stage or diluted to 1 mL with21-month control, N 5 5; 24-month control, N 5 5)
housed under identical conditions. buffer (5% acetonitrile in 5 mmol/L disodium phosphate,
pH 7.4). A solution containing amino acid standards was
Analysis of kidney function dried and coupled in the same manner. The coupling
efficiency was .99% under these conditions.Mean arterial pressure (MAP) was measured on the
day of sacrifice under anesthesia with nembutal (70 mL/
Apoptosis100 g body weight, IP). A polyethylene catheter was
placed in the right femoral artery for monitoring of arte- Apoptotic cells were detected by TUNEL method by
using ApopTag Peroxidase In Situ Apoptosis Detectionrial blood pressure by a transducer recorder (Blood Pres-
sure Analyzer; Micro-Med Inc., Louisville, KY, USA). Kit (Intergen Co., Purchase, NY, USA). Briefly, 4 mm
paraformaldehyde-fixed sections were deparaffinizedSerum creatinine was measured by Vitros CREA slides
(Johnson & Johnson Clinical Diagnostics Inc., Roches- and rehydrated in graded ethanol and then in phosphate-
buffered saline (PBS). Samples were pretreated by incu-ter, NY, USA). Animals were placed in metabolic cages
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Table 1. Age-dependent changes in weight, mean arterial pressure (MAP) and serum creatinine
Control AIIRA
months months
Parameters 18 21 24 21 24
Body weight g 765619 744628 813645 768620 83565
MAP mm Hg 10960.2 11664 11567 10864 11366
Serum creatinine mg/dL 0.7260.06 0.7760.15 0.8360.11 0.7660.12 0.6060.00
Body weight, MAP and serum creatinine increased with aging. No statistically significant changes occurred with treatment, although serum creatinine was numerically
lower at 24 months with AIIRA.
Northern blot hybridization
Total RNA from renal cortex was extracted by the
RNAzole B method (Tel-Test, Inc., Friendswood, TX,
USA). Twenty micrograms of total RNA were loaded
and fractionated by electrophoresis in 1% agarose gel
and were transferred to a nylon membrane. Mouse PAI-1
cDNA was labeled with [32P] dCTP, and hybridization
was performed in buffer [4 3 SSCP, 1 3 Denhardt’s,
1% sodium dodecyl sulfate (SDS), 100 mg/mL denatured
salmon sperm DNA, and 10% dextran sulfate] overnight
at 658C. The membrane was washed twice in 2 3 standard
saline citrate (SSC), 0.1% SDS for 20 minutes at 658C
and once in 0.1 3 SSC, 0.1% SDS at 658C for 20 minutes,
air-dried and exposed to XAR film (Kodak, Rochester,
NY, USA) in intensifying screen at 2708C for three
to five days. Autoradiographs were scanned by image
scanner JX-330 (Sharp, Tokyo, Japan), and the intensity
of the signals was measured by NIH image (National
Institutes of Health, Bethesda, MD, USA). The ratio of
specific message to the housekeeping gene GAPDH was
Fig. 1. Urinary protein excretion increased with aging. Treatment with
used to quantitate the expression for each tissue sample.angiotensin type 1 receptor antagonist (AIIRA) for six months signifi-
cantly reduced proteinuria. Symbols are (j) control; (d) AIIRA; *P 5
0.0017 compared with age-matched control. In situ hybridization for transforming growth factor-b1
35S-labeled sense and antisense riboprobes for mouse
transforming growth factor-b1 (TGF-b1) were prepared
as previously described [7] by transcription of thebation with proteinase K (2 mg/mL) for 15 minutes at
pmTGFb1-A plasmid from Dr. H.L. Moses, with inser-room temperature. Endogenous peroxidase was inacti-
tion of 974 bp cDNA fragment by T7 or Sp6 RNA poly-vated by 3% H2O2 in PBS for five minutes; sections were
merase (Ambion, Austin, TX, USA). In situ hybridiza-rinsed with PBS, immersed in TdT equilibration buffer,
tion was done as specified later in this article.and then incubated with TdT and digoxigenin-dUTP at
378C for 60 minutes. The reaction was stopped with buffer,
PAI-1 in situ hybridization and immunohistochemistryand antidigoxigenin peroxidase conjugate was applied
35S-labeled sense and antisense riboprobes for PAI-1and incubated for 30 minutes. The slides were developed
were prepared as previously described [7] by transcrip-by using diaminobenzidine substrate. Negative control
tion of the pCR II plasmid (Invitrogen, Carlsbad, CA,slides were incubated with TdT buffer without TdT. Posi-
USA) with insertion of cDNA fragment by SP6 or T7tive control slides were treated with DNAse (10 mg/mL;
RNA polymerase (Ambion). Sections were dewaxed inSigma, St. Louis, MO, USA). Apoptosis in the cortex of
xylene, hydrated in graded ethanols, and then fixed inkidney was assessed by scoring the TUNEL-positive cells
4% paraformaldehyde. After treatment by proteinase Kas an index of apoptosis in glomeruli, tubules, and inter-
and triethanolamine/acetic anhydride, sections were de-stitium at 3100 magnification in 15 sequential high-
hydrated in ethanol and air dried. Hybridization was donepower fields. Apoptosis score was graded from 0 to 4
in buffer (50% formamide, 10% dextran sulfate, 8 mmol/Lbased on number of TUNEL-positive cells from 0,
,25%, 25 to 50%, 50 to 75%, to .75% in each field. dithiothreitol, 0.2 mg/mL tRNA, 300 mmol/L NaCl, 10
(Editor’s Note: Panels for Figs. 2, 3 and 5 ap-
pear on both page 2428 and 2429.)
Fig. 2. Aortic wall thickness ratio. Aortic wall
thickness ratio was significantly decreased in
aging rats after treatment with AIIRA. (A)
Twenty-one–month AIIRA vs. 21-month con-
trol, P 5 0.006; 24-month AIIRA vs. 24-month
control, P 5 0.0027; 24-month AIIRA vs. 18-
month control, P 5 0.018. Symbols are: ( )
control; ( ) AIIRA. (B) Cross-section of
aorta in 24-month control (left) and 24-month
AIIRA (right; periodic acid-Schiff, 3100).
Fig. 3. Histopathologic changes in control ( )
and AIIRA-treated ( ) aging rat kidney.
AIIRA treatment for 6 months decreased glo-
merulosclerosis versus age-matched control to
levels even lower than 18-month baseline
level. Glomerulosclerosis, tubular atrophy,
and interstitial fibrosis were present at 18-
month control (A) and increased with further
aging (B and C ); treatment with AIIRA for
six months decreased glomerulosclerosis with
proportional changes in tubulointerstitial in-
jury (D; Masson’s trichrome stain, 3100).
Fig. 5. Apoptosis in aging rat kidneys at 24 months. Apoptosis wasFig. 4. Collagen content as percentage of total protein in kidney. Colla-
significantly reduced after treatment with AIIRA for six months (P ,gen content increased with aging (18-month control vs. 24-month con-
0.05 vs. 21-month and 24-month controls). Symbols are: ( ) control;trol, P , 0.05) and was decreased after treatment with AIIRA for six
( ) AIIRA. Apoptosis was present in tubules (B 3400, C 340) andmonths (24-month AIIRA vs. 24-month untreated control, P , 0.05).
glomerular cells (A and B 3400). Apoptotic cells in the cortex of kidneySymbols are: ( ) control; ( ) AIIRA.
were diminished in the 24-month AIIRA-treated kidney (D 340).
Fig. 2. Continued.
Fig. 3. Continued.
Fig. 5. Continued.
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Fig. 6. Transforming growth factor-b (TGF-b) mRNA expression by in situ hybridization in aging rats. TGF-b mRNA was diffusely expressed
at low level in glomeruli (A) and interstitium (B) of 18-month control rats; increased TGF-b mRNA expression was present in glomeruli (C), tubules,
and interstitium in the renal cortex (D). TGF-b mRNA expression in kidney was attenuated after treatment with AIIRA for six months (E).
mmol/L Tris-HCl, 5 mmol/L ethylenediaminetetraacetic washed in TEN at 378C for 10 minutes, in 2 3 SSC and
0.1 3 SSC each twice at 688C for 15 minutes. Sectionsacid (EDTA), 0.02% polyvinylpyrolidone, 0.02% Ficoll,
and 0.02% bovine serum albumin) overnight at 508C. Sec- were then dehydrated in ethanol and air dried, dipped
in photographic emulsion, and exposed at 48C for 10tions were washed in 5 3 SSC, 20 mmol/L b-mercapto-
ethanol at 508C for 15 minutes, in 2 3 SSC, 50% for- days. The sections were developed with D-19 developer
(Kodak) and counterstained with toluidine blue. Controlmamide at 688C for 20 minutes, in TEN twice at 378C for
10 minutes, treated with RNase at 378C for 30 minutes, in situ hybridization was done with sense probes.
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Statistical analysis
Results are expressed as mean 6 SEM. Statistical dif-
ference was assessed by a single factor variance (analysis
of variance; ANOVA) followed by unpaired t-test as ap-
propriate. Nonparametric data were compared by Mann–
Whitney U-test. A P value , 0.05 was considered to be
significant.
RESULTS
Renal functional changes
Body weight, MAP, and serum creatinine increased
slightly with aging from 18 to 24 months (Table 1). Serum
creatinine level was numerically lower at 24 months in
AIIRA-treated rats, although not statistically significant.
The MAP remained in the normal range, indicating the
absence of hypertension with aging in this Sprague-Daw-
ley species. However, urinary protein excretion increased
progressively with aging. Treatment with AIIRA for six
months significantly decreased this urinary protein excre-
tion compared with age-matched untreated control rats
(P 5 0.0017 vs. 24 month control; Fig. 1).
Morphological changes
With aging, aortic wall thickness ratio was 0.13 6 0.008
at 18 months, 0.15 6 0.006 at 21 months, and 0.14 6
0.003 at 24 months. Treatment with AIIRA significantly
reduced aortic wall thickness ratio compared with age-
matched controls (at 21 months, 0.12 6 0.008 vs. controls
0.15 6 0.006, P 5 0.006; at 24 months, 0.10 6 0.005 vs.
Fig. 7. Plasminogen activator inhibitor-1 (PAI-1) mRNA expression controls 0.14 6 0.003, P 5 0.0027; Fig. 2). The aorta wallin kidney. PAI-1 expression was slightly increased from 18 to 24 months
thickness ratio after treatment with AIIRA for 6 monthsin aging rats. Treatment with AIIRA decreased PAI-1 mRNA expres-
sion in aging kidney to levels about 30% of control by the age of 24 was even lower than that of 18-month control rats
months. Symbols are: ( ) control; ( ) AIIRA. (AIIRA 24 months 0.10 6 0.005 vs. 18-month control
0.13 6 0.008, P 5 0.018; Fig. 2A). In control rats, glomer-
ulosclerosis, tubular atrophy, dilation and interstitial fi-
For immunostaining, tissue was fixed in 4% paraform- brosis were present at the age of 18 months and were
aldehyde overnight at 48C, routinely processed, and em- more extensive by 24 months (Fig. 3, p. 2429). The glo-
bedded in paraffin. Four mm sections were treated by 3% merulosclerosis index tended to increase with aging (SI:
hydrogen peroxidase for 10 minutes, exposed to power 18 months 0.37 6 0.14, 21 months 0.38 6 0.12, 24 months
block (BioGenex Laboratories, San Ramon, CA, USA) 0.49 6 0.12; Fig. 3, p. 2428). In 24-month-old rats, there
for 45 minutes, incubated with rabbit anti-rat PAI-1 anti- was occasional focal and segmental glomerular sclerosis
body (American Diagnostica, Inc., Greenwich, CT, USA)
in addition to global glomerulosclerosis (Fig. 3, p. 2429).overnight, and rinsed twice with PBS. Biotinylated goat
Treatment with AIIRA for six months significantly de-anti-rabbit Ig (BioGenex Laboratories) was added and
creased glomerulosclerosis compared with age-matchedincubated for 45 minutes, followed by peroxidase-conju-
control (SI: AIIRA 24 months 0.06 6 0.02 vs. 24-monthgated streptavidin for 45 minutes. After rinsing three
control 0.49 6 0.12, P 5 0.0082), to levels even lowertimes with PBS, diaminobenzidene was added as a chro-
than 18-month baseline (SI: 18-month control 0.37 6magen. Slides were counterstained with hematoxylin.
0.14 vs. AIIRA 24 months, P 5 0.014; Fig. 3).PAI-1 glomerular expression was evaluated by a semi-
quantitative score. Scores of 0 to 4 represent negative,
Collagen contenttrace, ,10%, 10 to 25%, and .25% staining, respec-
Collagen in renal cortex, expressed as a percentagetively, in each glomerulus. Negative controls without the
of total protein, increased with aging (% collagen/totalprimary antibody were done at the same time and showed
no staining. protein: 18 months 2.5 6 0.9, 21 months 4.1 6 0.2, 24
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Fig. 8. PAI-1 protein and mRNA expression in the kidneys of control and AIIRA-treated aging rats. PAI-1 mRNA was increased in aging rat
kidney, with signals detected primarily in sclerotic glomeruli (B and G), arteriole in endothelium and vascular smooth muscle cells (F ) and some
tubules (D and G) of renal cortex. PAI-1 mRNA was present in glomerular parietal epithelial cells, mesangial cells, and endothelial cells. PAI-1
mRNA expression was markedly diminished in rats treated with AIIRA for six months (H, darkfield; J, lightfield) compared with age-matched
untreated control rats. PAI-1 protein expression in control (A, C, and E ) and AIIRA-treated rats (I ) showed patterns parallel to mRNA expression.
months 5.0 6 0.7, 24 months vs. 18 months, P 5 0.0106). Apoptosis
Treatment with AIIRA for six months significantly re- During aging, the kidneys of old control rats demon-
duced the collagen content compared with age-matched strated increased apoptosis by TUNEL staining of pre-
control rats (% collagen/total protein: AIIRA 24 months dominantly tubular epithelial cells in the cortex (apopto-
sis scoring of 18 months, 21 months, and 24 months:3.1 6 0.5 vs. 24-month control rats, P , 0.05; Fig. 4).
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Fig. 8. Continued.
0.80 6 0.05, 1.56 6 0.33, 1.06 6 0.23, respectively), with aging rats were numerically but not statistically increased
occasional TUNEL-positive cells in glomeruli. Apoptosis from 18 to 24 months (PAI-1/GAPDH density ratio: 18
showed a maximum at 21 months. Apoptotic cells in the months 0.90 6 0.24, 21 months 0.96 6 0.30, 24 months
cortex of kidney were decreased in the 24-month AIIRA- 0.99 6 0.05; Fig. 7 A, C). The level of PAI-1 mRNA
treated group (apoptosis scoring: 24-month AIIRA-treated was attenuated after treatment with AIIRA for three
rats 0.33 6 0.16 vs. 21-month control or 24-month con- months (0.76 6 0.03, vs. 24-month control, P , 0.05).
trol, P , 0.05, respectively). The 24-month treated kid- After a six-month AIIRA treatment, PAI-1 expression
neys displayed no apoptotic cells in the glomeruli, and was about one third of untreated rats (0.34 6 0.05, P ,
few apoptotic cells were found in tubular and interstitial 0.05 compared with 24-month control rats; Fig. 7 A, C).
cells (Fig. 5). In situ hybridization revealed high-level PAI-1 mRNA
expression in untreated aging rat kidneys, especially inTGF-b1 mRNA expression
24-month-old untreated rats (Fig. 8 B, D, F), in contrastIn situ hybridization for TGF-b showed diffuse moder-
to minimal PAI-1 mRNA expression that we observedate signal in glomeruli (Fig. 6A), with locally increased
previously in kidney in 10-week-old male Sprague-Daw-expression on tubular and interstitial cells in the renal
ley rats [6]. Strong PAI-1 mRNA signals were detectedcortex of 18-month-old control rats (Fig. 6B). TGF-b
primarily in sclerotic glomeruli (Fig. 8B), arterioles (Fig.mRNA signal was up-regulated in 24-month-old rat kid-
8F), and some tubules (Fig. 8D). Glomerular parietalneys (Fig. 6 C, D). The TGF-b signal appeared attenu-
epithelial, mesangial, and endothelial cells, small vesselated after AIIRA treatment for six months (Fig. 6E).
endothelial and smooth muscle cells, and tubular epithe-Sense probes showed no specific signal.
lial cells showed signal. PAI-1 mRNA expression was
PAI-1 mRNA and protein expression markedly diminished in AIIRA-treated rats (Fig. 8 H, J)
compared with age-matched untreated control rats. PAI-1Plasminogen activator inhibitor-1 mRNA levels as-
sessed by Northern blot analysis in the renal cortex of protein expression in control (Fig. 8 A, C, and E) and
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mum antihypertensive dose of ACEI, progression was
significantly reduced in the hypertensive 5/6 nephrec-
tomy rat model [18]. Remarkably, in this model, sclerosis
was even further affected by a higher dose ACEI that had
no further hemodynamic effect. There was regression of
sclerosis, that is, less sclerosis at autopsy than at biopsy
four weeks earlier, in half of the rats receiving this treat-
ment [18]. This effect was linked to decreased PAI-1 ex-
pression (abstract; Nakamura et al, J Am Soc Nephrol 10:
665A, 1999). In previous experiments with the nonhyper-
tensive, radiation-induced nephropathy rat model, we also
found protection against injury with ACEI or AIIRA. Of
relevance to aging, after 24 weeks, sclerosis was even
lower in ACEI- or AIIRA-treated radiated rats than
Fig. 9. Quantitation of immunostaining of PAI-1 protein in glomeruli age-matched untreated control animals. These findingsin aging rats. AIIRA treatment for six months significantly reduced
were also linked to decreased PAI-1 expression [7]. InPAI-1 protein expression by the age of 24 months compared with age-
matched controls and to levels even lower than 18-month controls. the present study, we extend these observations to the
Symbols are: ( ) control; ( ) AIIRA. aging rat, demonstrating that sclerosis in the aging kidney
can even be remodeled by inhibition of angiotensin and
that the effect is linked to modulation of PAI-1 expression.
The RAS is altered in aging, with reduced plasma reninAIIRA-treated rat (Fig. 8I) showed patterns that paral-
activity and aldosterone levels, partially compensated forleled the in situ results. PAI-1 scoring in AIIRA-treated
by increases in the density of Ang II receptors in agingrats at 24 months was significantly decreased compared
rats [19] and in older patients [20], which may be relatedwith the level of 24-month and even 18-month control
to the age-related fibrosis in kidney and in heart. How-rats (PAI-1 scoring: 24-month AIIRA 0.49 6 0.10 vs.
ever, plasma levels do not adequately reflect tissue activ-24-month control 0.90 6 0.07, P , 0.05; 24-month AIIRA
ity of the RAS, in which activity is modulated by at leastvs. 18-month control 1.05 6 0.02, P , 0.05; Fig. 9).
two receptors. Selective Ang II type I receptor blockers
have the potential to directly decrease the hypertensive
DISCUSSION and growth-promoting actions of Ang II at the AT1
receptor, while leaving the apoptosis-promoting effectsProgressive deterioration of the kidney is common to
many renal diseases. The structural injuries that lead to of the AT2 receptor intact [21, 22].
Apoptosis is thought to play an important role in thethis progressive loss of function consist of focal segmental
glomerulosclerosis and tubulointerstitial fibrosis and at- regulation of renal cell number in both healthy and dis-
eased kidneys. Apoptosis may serve as a healing mecha-rophy. These processes were previously thought to be
inexorable, regardless of the primary disease. However, nism by minimizing stimulation of profibrotic mecha-
nisms, but apoptosis in disproportionate amounts couldrecent observations point to the possibility of regression
of sclerosis [12, 13]. promote scarring by removing cells that may effect heal-
ing and matrix reabsorption [12]. Apoptosis of tubularAging of the kidney is a progressive process in which
it appears that the equilibrium between the deleterious and interstitial cells has been previously documented in
several models of tubulointerstitial diseases, includingvasoconstrictor/profibrotic local mediators and the bene-
ficial vasodilator/antifibrotic autacoids is progressively ureteral obstruction [22]. In this model, decreased apo-
ptosis by null mutation of the AT2 receptor was associ-displaced toward the former. The activity of the RAS
may contribute to promoting sclerosis, particularly in ated with worsened tubular cell loss and fibrosis [22]. In
contrast, a progressive and sustained increase in apo-aging, as a result of its direct hemodynamic and growth
factor effects, its induction of other growth factors, and ptotic cells in the glomerular, tubular, and interstitial
cells of rat remnant kidneys occurred during the develop-also its induction of inhibitors of matrix degradation,
such as PAI-1 [14]. ment of glomerulosclerosis [23], suggesting that apopto-
sis might contribute to the acellular scarred end-stageIn aging Wistar (WAG)/Rij rats, ACEI in usual anti-
hypertensive doses was shown to reduce proteinuria. This kidney in this setting. That these findings may also be
relevant to aging in humans is suggested by the predomi-treatment delayed development and ameliorated pro-
gression of age-related sclerosis in large arteries and the nance of FAS and decrement of bcl2, a pattern of in-
creased programmed cell death in kidneys of aging pa-kidney [15–17]. The benefits and mechanisms of reducing
RAS activity have been extensively investigated in mod- tients with advanced chronic renal failure [24]. We found
increased apoptosis of tubular epithelial cells in associa-els of progressive glomerulosclerosis. With the usual mini-
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tion with fibrosis in aging rats, consistent with previous disease in human and animal models [14]. Increased PAI-1
has been linked not only to human atherothromboticresults [25]. The apoptosis was focal, but in involved
tubules, most cells were TUNEL positive, suggesting disorders and myocardial infarction [36], but also to vas-
cular sclerosis [14]. Furthermore, PAI-1 expression has“drop out” of individual nephron segments. Furthermore,
improvement of the renal morphology with AIIRA been tightly correlated with sites of sclerotic glomerular
injury [7]. In the present study, we found that PAI-1treatment was associated with reduced tubular apoptosis.
These findings of decreased apoptosis with AIIRA de- expression, both mRNA and protein, was increased with
aging, with marked increase in PAI-1 expression at 24spite that unblocked AT2 receptor indicate that AT2
receptor did not play a major role in promoting apoptosis months of age. In contrast, our previous study in 10-week-
old normal rats showed very low-level PAI-1 mRNAin this setting. However, it is possible that AT2 receptor
has a role in mediating the remaining, albeit decreased and protein expression [6]. Increased PAI-1 mRNA and
protein expression in aging localized to sclerotic glomer-apoptosis. Our results also demonstrate that high-dose
AIIRA treatment for six months not only improves renal uli and the fibrotic interstitium. AIIRA treatment sig-
nificantly reduced the up-regulated PAI-1 expression infunction by decreasing proteinuria, but it also signifi-
cantly decreases glomerulosclerosis compared with age- aging kidney, reduced the scarring and collagen content
in aging kidney, and even induced regression after treat-matched control to levels even lower than the 18-month
baseline level. These results contrast with previous re- ment for six months. Thus, these data support the postu-
late that enhanced degradation of ECM was unmaskedports of aging rodents that showed ACEI reduced inter-
stitial fibrosis, but had no effect on glomerulosclerosis by inhibiting PAI-1.
We conclude that high-dose AIIRA not only slows[8, 9]. This discrepancy likely relates to the added bene-
fits of higher dose of angiotensin inhibition in our study. the progression of glomerular and vascular sclerosis in
aging, but can also induce regression of these processesPathologic remodeling of mesangial matrix after glo-
merular injury is a central feature of glomerular scarring. independently of its hemodynamic actions. These mech-
anisms appear to involve modulation of cortical cell turn-Increased expression of ECM components such as fi-
bronectin, laminin, and collagen is one of the characteris- over and inhibition of PAI-1 expression.
tics of abnormal mesangial ECM remodeling. Increased
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